Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 7/20 | 0.40 |
| ▸ | REN | P00797 | 2/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | AGXT | P21549 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6884561 | 0.80 | METAP2 (0.35) | METAP2RENTACR1NAAAKCNA5 | |
| SCHEMBL9209896 | 0.77 | METAP2 (0.63) | METAP2 | |
| SCHEMBL6878395 | 0.77 | METAP2 (0.46) | METAP2RENTACR1 | |
| SCHEMBL6882901 | 0.73 | METAP2 (0.53) | METAP2 | |
| SCHEMBL6548680 | 0.71 | REN (0.40) | RENTACR1NAAAKCNA5IDO1 | |
| SCHEMBL24597253 | 0.69 | IDO1 (0.50) | RENNAAAKCNA5IDO1AGXT | |
| SCHEMBL6883893 | 0.69 | TACR1 (0.43) | METAP2TACR1IDO1 | |
| SCHEMBL13103437 | 0.67 | KCNA5 (0.47) | RENTACR1NAAAKCNA5IDO1 | |
| SCHEMBL10348013 | 0.67 | REN (0.39) | RENTACR1NAAAKCNA5IDO1 | |
| SCHEMBL22588318 | 0.65 | REN (0.44) | RENTACR1NAAAKCNA5IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6803382-B2 | 1-OXASPIRO(2,5)OCTAN-6-OL DERIVATIVES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-10-12 | — | — | US | disclosed |
| US-20030134896-A1 | Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134896-A1 | Novel angiogenesis inhibitors and pharmaceutical and cosmetic use thereof | VEGFA, KDR, FLT1 | METAP2 2357/4885REN 2405/4885TACR1 2450/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.